Global
endometrial
cancer therapeutics market is expected to witness significant
growth as there are less number of approved drugs for treatment of endometrial
cancer, leading to an increased opportunity for the drug manufacturers. High
prevalence of cancer and rising demand for safe and effective medications can
be attributed as the major drivers of this market. The regulatory bodies such
as USFDA and EMA are supporting the growth of the global market by providing increased
funding, designations and grants for speeding up the drug development process.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market/report-sample
Endometrial
cancer is the malignancy that develops in the layers of the cells that forms
endometrium, lining of uterus. The precise cause of endometrial cancer is still
unknown but it is assumed that estrogen may be involved in developing
endometrial cancer, as estrogen helps in the formation of the endometrial
lining. Obesity, polycystic ovary syndrome, infrequent periods and history of
endometrial polyps can increase the risk of endometrial cancer. Women with
diabetes, high blood pressure or breast cancer are at a greater risk of having endometrial
cancer. Abnormal vaginal bleeding, bleeding between periods or after menopause,
lower abdominal cramps or clear vaginal discharge after menopause are some of
the main symptoms of endometrial cancer.
Though, chemotherapy is projected to have the maximum share in the global
endometrial cancer therapeutics market owing to high adoption rate of
chemotherapy over surgical treatment and radiation therapy in oncology. Also, carboplatin
and paclitaxel are recommended as chemotherapeutic agents for first line of
therapy in majority of the cases, which increases demand for these products. FDA
recently approved IXEMPRA (ixabepilone) for use in endometrial cancer treatment
which is likely to increase the growth of market during in the future.
Request for Table of
Content at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market/toc-sample
Geographically,
North America is expected to be the largest market for endometrial cancer therapeutics
treatment, owing to the large number of research and development activities ad high
healthcare expenditure. Europe is expected to hold the second largest share in
the global market owing to growing product availability in the region.
Some of the key
players operating in the global endometrial cancer therapeutics market are AstraZeneca Plc., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc. and R-Pharm-US LLC.
